PHAM QUANG X (CEO and Chairman) sold 6.5% of their position (12.76K shares) of CADRENAL THERAPEUTICS, INC. on the open market
Open‑market sale worth $69.5K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 5/29/2026ACC: 0001213900-26-062862
DirectorOfficer10% Owner· CEO and Chairman
Since Jan 2023
-12.76K
Net shares
Net seller
$69.5K
Total sold
3
Open market trades
0B · 3S
3
Total transactions
12.76K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−6.48K
Price / share
$5.76
Trade value
$37.30K
% of position
3.3%
5/11/2026
194.92K→188.45K
Common Stock
Direct
Shares
−3.30K
Price / share
$5.28
Trade value
$17.41K
% of position
1.8%
5/12/2026
188.45K→185.15K
Common Stock
Direct
Shares
−2.99K
Price / share
$4.93
Trade value
$14.74K
% of position
1.6%
5/28/2026
185.15K→182.16K
Total
Net shares
−12.76K
Net value
-$69.45K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/11/2026 | S · Sale | −6.48K | $5.76 | $37.30K | 3.3% | 194.92K | 188.45K |
| Common Stock Direct | 5/12/2026 | S · Sale | −3.30K | $5.28 | $17.41K | 1.8% | 188.45K | 185.15K |
| Common Stock Direct | 5/28/2026 | S · Sale | −2.99K | $4.93 | $14.74K | 1.6% | 185.15K | 182.16K |
| Total | −12.76K | -$69.45K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned200K
Total
200K indirect200K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 200K | Indirect |
| Total | 200K | 200K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported